Tesamorelin is a synthetic analogue of human growth hormone-releasing factor (GHRF) designed to stimulate GHRF receptor activity. Research has examined its effects on endogenous growth hormone secretion and downstream signaling involving insulin-like growth factor 1 (IGF-1) and IGF-binding protein 3 (IGFBP-3).

As a research compound, tesamorelin is of interest for investigating growth hormone signaling, endocrine pathways, metabolic regulation, and the relationship between GHRF receptor activation and downstream physiological processes.

Tesamorelin is also an FDA-approved prescription medicine in specific formulations and for a specific indication. Current U.S. labeling indicates its approved use for reducing excess abdominal fat in HIV-infected adults with lipodystrophy; it is not indicated for general weight-loss management.